Ligand Pharmaceuticals (LGND) Profit After Tax Growth (1y) (2011 - 2026)
Ligand Pharmaceuticals (LGND) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 5.92 Bn | 5.14 Bn | 48.45 Mn | 68.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.56% |
| Dec 31, 2025 | 244.06% |
| Sep 30, 2025 | 1,735.15% |
| Jun 30, 2025 | 109.34% |
| Mar 31, 2025 | -149.28% |
| Dec 31, 2024 | -270.93% |
| Sep 30, 2024 | 30.19% |
| Jun 30, 2024 | -2,366.86% |
| Mar 31, 2024 | 105.34% |
| Dec 31, 2023 | 204.02% |
| Sep 30, 2023 | -2,642.82% |
| Jun 30, 2023 | 355.87% |
| Mar 31, 2023 | 372.66% |
| Dec 31, 2022 | -447.43% |
| Sep 30, 2022 | -97.06% |
| Jun 30, 2022 | -102.91% |
| Mar 31, 2022 | -167.58% |
| Dec 31, 2021 | -155.44% |
| Sep 30, 2021 | 304.79% |
| Jun 30, 2021 | 39.12% |